Pentixapharm Holding AG, focused on the development of first-in-class radiopharmaceuticals, has announced the price range for its planned IPO on the Prime Standard of the Frankfurt Stock Exchange. The proceeds are intended to support the further development of the theranostics product pipeline, including two lead candidates that have shown promising results in clinical trials.
Pentixapharm Holding AG has announced the price range for its upcoming IPO. This is between EUR 4.70 and EUR 6.00 per share. A total of up to 3.9 million new shares will be offered. Pentixapharm, a biopharmaceutical company specializing in the development of innovative radiopharmaceuticals, aims with the IPO to secure fresh capital for clinical development and strategic expansion. The subscription period begins on September 24, 2024 and runs until October 1, 2024.
The expected gross cash inflow from the placement of the shares is expected to amount to EUR 18.3 to 23.4 million. These funds will primarily be used for the further development of the promising product pipeline, including the lead candidates Ga68-PentixaFor and Y90-PentixaTher. In initial clinical trials, both compounds have shown potential to open up new therapeutic options in the field of blood cancer and other indications that have not yet been treated with radiopharmaceuticals.
With the upcoming IPO, Pentixapharm is taking an important step on the path to market maturity for its radiopharmaceuticals. PentixaFor, the lead candidate for the diagnosis of marginal zone lymphoma, is already in clinical phase III. CEO Dr. Hakim Bouterfa believes that Pentixapharm is now on the home straight with its IPO plans and is pleased with the positive feedback from investors. He wants to make the share attractive for investors who get in early. He explains: “The aim is to minimize the dilution of Eckert & Ziegler shareholders who will become Pentixapharm shareholders as a result of the spin-off from Eckert & Ziegler SE. The IPO will therefore only offer a limited number of shares. We are convinced that Pentixapharm will develop positively and want to achieve further milestones in the coming months.”
Pentixapharm Holding AG was founded in 2024 to absorb all shares held by Eckert & Ziegler SE in Pentixapharm AG, based in Würzburg, following the spin-off resolved by the Annual General Meetings of Eckert & Ziegler SE and Pentixapharm Holding AG on June 26, 2024. Pentixapharm Holding AG is to be listed in the Prime Standard of the Frankfurt Stock Exchange.
Pentixapharm AG is a biopharmaceutical company founded in 2019 that focuses on the development of innovative first-in-class radiopharmaceuticals based on ligands against the CXCR4 receptor. These are being tested both diagnostically and therapeutically against various hematological and solid tumors as well as cardiovascular, endocrine and inflammatory diseases.
Pentixapharm's clinical pipeline includes PentixaTher, a yttrium-90-based therapeutic for non-Hodgkin's lymphoma (NHL), and PentixaFor, a gallium-68-based companion diagnostic. Clinical trials for both compounds have already started with a dose-finding study for PentixaTher and a Phase III registration study for PentixaFor in marginal zone lymphoma in Europe. In addition, PentixaFor is being developed as a diagnostic tool for primary hyperaldosteronism (PA), a major cause of hypertension. Pentixapharm is currently preparing a US-centered Phase III study with PentixaFor in PA, which is expected to start in 2025.